Antengene Presents Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026
SHANGHAI and HONG KONG, Nov. 12, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune d...
Antengene Presents Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026
SHANGHAI and HONG KONG, Nov. 11, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune d...
Antengene Presents Latest Preclinical Results of Novel Cos-TCE Platform AnTenGager‑D2 in Rapid Oral Abstract Presentation at SITC 2026
SHANGHAI and HONG KONG, Nov. 9, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dise...
Antengene Announces First Patient Dosed in Phase I ATTRACT Study Evaluating ATG-201 (CD19 × CD3 TCE) for B Cell-Mediated Autoimmune Diseases
SHANGHAI and HONG KONG, Nov. 6, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dise...
Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026
SHANGHAI and HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026
SHANGHAI and HONG KONG, Oct. 9, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune di...
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026
SHANGHAI and HONG KONG, Oct. 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dise...
Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
SHANGHAI and HONG KONG, Sept. 21, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune di...
Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy
SHANGHAI and HONG KONG, Sept. 14, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune ...
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
SHANGHAI and HONG KONG, Aug. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
SHANGHAI and HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026
SHANGHAI and HONG KONG, July 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
SHANGHAI and HONG KONG, July 13, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
* ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors * K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China * Antengene r...
Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
SHANGHAI and HONG KONG, June 10, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune di...
Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
SHANGHAI and HONG KONG, June 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune di...
Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
SHANGHAI and HONG KONG, May 28, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline
SHANGHAI and HONG KONG, May 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
